Product Information
CINACALCET HCL 30 MG TABLET is a generic product labeled by Major Pharmaceuticals, priced at $0.4114 per EA under NDC 00904750204. Its NADAC has been published 76 times since Apr 23, 2025.
FDA first approved this application on Apr 30, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The Low Outlier badge above means this manufacturer's average price in the Cinacalcet market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
30 mg/1
Manufacturer
Major PharmaceuticalsNDC
00904750204
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CINACALCET HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA209226FDA Approved
4/30/2018
TE Code
AB
On Market Since
1/29/2025
Pharmacological Classes
Price Statistics
The NADAC for CINACALCET HCL 30 MG TABLET has been published 76 times since Apr 23, 2025, and over the history we have for it it has risen 17.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4114 per EA |
|---|---|
| All-time high | $0.4156 (Feb 11, 2026) |
| All-time low | $0.3448 (Aug 20, 2025) |
| 52-week high | $0.4156 |
| 52-week low | $0.3573 |
| Median price | $0.3995 |
| Average price | $0.3855 |
| Largest weekly change | +7.2% (Nov 19, 2025) |
| Weeks tracked | 76 |
| Tracking since | Apr 23, 2025 |
Generic Alternatives
The matcher finds 8 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Major Pharmaceuticals manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Cinacalcet market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcium-sensing Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CINACALCET HCL 30 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for CINACALCET HCL 30 MG TABLET, manufactured by Major Pharmaceuticals, is $0.4114 per EA (NDC 00904750204), effective Sep 30, 2026.
How has the price of CINACALCET HCL 30 MG TABLET changed over time?
Over the history we have for it, the NADAC for CINACALCET HCL 30 MG TABLET has risen 17.3%. It has been tracked across 76 weekly CMS publications since Apr 23, 2025.
What are the highest and lowest recorded NADAC prices for CINACALCET HCL 30 MG TABLET?
Since Apr 23, 2025, the NADAC for CINACALCET HCL 30 MG TABLET has ranged from a low of $0.3448 (Aug 20, 2025) to a high of $0.4156 (Feb 11, 2026), with a median of $0.3995 per EA.
Are there cheaper alternatives to CINACALCET HCL 30 MG TABLET?
Yes. 8 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CINACALCET HCL 30 MG TABLET, is $0.4030 per EA — about 2% below CINACALCET HCL 30 MG TABLET.
Who manufactures CINACALCET HCL 30 MG TABLET?
CINACALCET HCL 30 MG TABLET (NDC 00904750204) is labeled by Major Pharmaceuticals, and CMS classifies it as a generic product.